Royal London Hospital
London, England, E1 1BB, United Kingdom
Location status: Recruiting
Location contact
Christopher Uff, Dr
PRINCIPAL_INVESTIGATOR
Christopher Uff, Prof
CONTACT
Maria Roldan, Dr
CONTACT
Maria Roldan, MSc
SUB_INVESTIGATOR
NCT Number: NCT06453733
The clinical investigation aims to advance the Crainio device, designed for non-invasive intracranial pressure (ICP) monitoring. This feasibility study involves 54 participants over a 12-month period and seeks to collect cerebral photoplethysmogram signals alongside concurrent invasive ICP measurements in patients with traumatic brain injury. The primary objective is to establish the diagnostic accuracy of the Crainio device, aiming for at least 90% sensitivity and specificity in detecting raised ICP (above 20 mmHg). Secondary objectives include evaluating patient-related factors such as skin tone, skull thickness, and skull density, as well as the tolerability and acceptance of the device by both patients and healthcare professionals.
Interested in participating?
Request Info16 year–99 year
All sexes
Interventional
Not applicable
London, England, E1 1BB, United Kingdom
Location status: Recruiting
Christopher Uff, Dr
PRINCIPAL_INVESTIGATOR
Christopher Uff, Prof
CONTACT
Maria Roldan, Dr
CONTACT
Maria Roldan, MSc
SUB_INVESTIGATOR
Intracranial pressure (ICP) is routinely monitored in patients suffering from traumatic brain injury (TBI). Raised ICP can result in compression of the cerebral vasculature and subsequent reduction in oxygen and nutrient delivery to the brain leading to significant morbidity and mortality. In fact, raised ICP is the most common cause of death in patients with severe TBI.
Standard ICP monitoring requires insertion of a cranial bolt into the skull through which an electrical transducer is inserted. Alternatively, an intra-ventricular catheter is inserted through a burr hole. Both of these monitoring methods are associated with risks including haemorrhage and infection, as well as delay in establishing emergency monitoring and limiting it to hospitals that have neurosurgery.
There has been much research in recent years to find a method for measuring intracranial pressure noninvasively (nICP), including measurement of pressure in the retinal veins, measurement of eardrum displacement, transcranial Doppler ultrasonography and imaging-based solutions. These methods all require considerable user intervention and are non-continuous.
This project aims to collect cerebral photoplethysmogram signals and concurrent invasive ICP measurements from patients with traumatic brain injury to develop Crainio machine learning (ML) algorithms. The core intellectual property (IP) of this continuous external monitoring ICP system was originally developed by academics in the lab of Professor Kyriacou at City, University of London. Crainio is a spin-out company that was created to industrialise and commercialise this research on an exclusive basis.
The device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that estimate an absolute value of ICP.
The basic science behind this method for measuring ICP is that changes in the extramural arterial pressure affect the morphology of the recorded optical pulse, so analysis of the acquired signal using an appropriate algorithm will enable calculation of nICP. The reported nICP will provide screening at the triage stage, indicating the need for imaging or rapid intervention (such as haematoma evacuation) and guide head injury management, notably ICP-targeted treatment regimes. Ultimately this could lead to significant improvements in secondary injury-related mortality, length of hospital stay and reduced post-trauma disability.
This feasibility study aims to collect the clinical data with which to train the nICP algorithms to the point that they can detect raised intracranial pressure (ICP>20 mmHg) with sufficient sensitivity and specificity that Crainio device can be regulated for clinical use.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that will estimate ICP offline.
Other names: nICP probe, Crainio system
Time frame: 12 hours record per patient
Generate a nICP model offline with a sensitivity above 90% to discriminate ICP values over 20 mmHg.
Time frame: 12 hours record per patient
Generate a nICP model offline with a specificity above 90% to discriminateICP values over 20 mmHg.
Time frame: 1 classification per patient (3 minutes)
Evaluating the effect on the nICP model of patient-related factors such as the skin tone.
Time frame: 1 measurement per patient (3 minutes)
Evaluating the effect on the nICP model of patient-related factors such as the skull thickness.
Time frame: 1 classification per patient (1 minute)
Evaluating the effect on the nICP model of patient-related factors such as the skull density.
Time frame: 1 form per patient (5 minutes)
Customised form to assess the acceptance of the device by the healthcare proffesionals.
Time frame: 12 hours record per patient
Evaluate the device safety by monitoring the development of possible advers effects or events in the patients while data is acquired
Contact information is provided by the study sponsor or research team.
Crainio Ltda
Industry
Crainio Non-invasive Intracranial Pressure Monitor for Traumatic Brain Injury: Product Development
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07732374
Behavior, Brain Concussion
Boise, Idaho, United States
View Trial DetailsNCT07455136
Brain Diseases, Brain Injuries
Sacramento, California, United States
View Trial DetailsNCT05236010
Brain Diseases, Brain Injuries
Minneapolis, Minnesota, United States
View Trial DetailsNCT07719595
Brain Diseases, Brain Injuries
Stony Brook, New York, United States
View Trial Details